Welcome to LTZ Therapeutics, the pioneering biotech startup headquartered in Redwood City, California. With an impressive $10 million raised in pre-Series A funding from investors Qiming Venture Partners USA, and 顺为资本 Shunwei Capital,  and led by visionary founder Robert Li, LTZ Therapeutics is transforming lives through the development of novel immunotherapies. Driven by a relentless pursuit of innovation, our immunotherapy-focused biotech company is dedicated to improving clinical outcomes for patients with cancer and other diseases where there is an unmet clinical need. We harness the power of innate immunity and Treg cells, leveraging cutting-edge reverse translational science and emerging disease biology to break new ground in the biotech industry.

 At LTZ Therapeutics, we believe that innate immunity, such as macrophages, and the elimination of immunosuppression, including T regulatory cells and cancer-associated fibroblasts, hold tremendous potential for developing innovative and effective therapies. Our proprietary innate engager platform activates macrophages and natural killing (NK) cells, resulting in direct anti-tumor and anti-immunosuppressive cell killing, inflammation in the tumor microenvironment, and the activation of adaptive immunity and long-term memory. With operations spanning across Redwood City, California, Shenzhen, China, and a team in Heidelberg, Germany, LTZ Therapeutics is at the forefront of developing immunotherapies that overcome resistance and boost anti-tumor immunity.